SCY001P – Method To Treat Brain Trauma Injury
Scythian’s first patent application covers a two-drug combination therapy for concussive treatment. That is, the combined use of an NMDA antagonist plus a CB2 agonist, either cannabinoid or non-cannabinoid. NMDA antagonists inhibit white blood cell activity within injured brain tissue, stopping cytokine release and further brain damage. CB2 agonists modulate the inflammatory response itself, easing the initial swelling and the resulting pressure of injured brain tissue against the skull.
This patent application also covers the combination of a NMDA receptor antagonist plus a FAAH inhibitor. FAAH inhibitors also stop white blood cell infiltration and resulting cytokine release through different chemical pathways, achieving similar results post-concussion without the use of cannabinoids or CB2 agonists.
SCY002P – Method To Treat Gastrointestinal Inflammation
Scythian’s second patent filing covers methods and compositions for treating gastrointestinal inflammation. This includes the use of the cannabinoid CBD, the same CB-2 agonist covered in our concussion treatment combination, together with an NMDA receptor or FAAH inhibitor to control intestinal inflammation in chronic diseases such as irritable bowel syndrome and Crohn’s disease. These diseases are characterized by chronic and sometimes severe inflammation in the gastrointestinal tract caused by an overactive immune system and inflammatory response, due either to autoimmunity or hypersensitivity.nyDocuments.do?lang=EN&issuerNo=00033348
Outstanding Shares: 29,333,588